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1. Introduction 
One of the most characteristic features of the aged is a change in body composition and 
human cross-sectional and longitudinal studies consistently demonstrate gain in fat mass 
and decline in lean mass (Attaix et al., 2005). Skeletal muscle mass is gradually reduced 
through both atrophy and loss of myofibers, and along with this connective tissue and 
intramyocellular lipids increase (Fig. 1) (St-Onge, 2005). Although sarcopenia is widely 
recognized it remains poorly understood and has not received appropriate attention until 
quite recently. Sarcopenia is often assumed to have a multi-factorial background (Adamo 
and Farrar, 2006; Attaix et al., 2005; Paddon-Jones and Rasmussen, 2009; Roth et al., 2006; 
Solomon and Bouloux, 2006). A sedentary life-style combined with periods of prolonged 
bed-rest during illnesses has well-established detrimental effects on muscle mass and 
function (Janssen et al., 2002). Skeletal muscles do not only generate the power to let us 
move but collectively they are a highly significant component of the systemic metabolic 
homeostasis machinery. The progressive loss of muscle mass with advancing age is evident 
in both the ‘healthy’ aging population and specialist patient populations. The reduced 
functional muscle mass is associated with increased morbidity, frailty and reduced quality 
of life (Baumgartner et al., 1998a). The prevalence of sarcopenia increases with about 5% per 
year and typically begins in the fourth decade of life (Baumgartner et al., 1998b). After the 
age of 50 years 1-2 % of the muscle mass is lost annually. Individuals with clinically 
manifest sarcopenia have 4 times greater risk of disability, three times greater risk of balance 
impairment, and 3 times greater risk of falling (Baumgartner et al., 1998b). Sarcopenia is the 
single most common etiology to falls and fall-associated fractures in elderly.  
1.1 Regulation of muscle mass and tentative mechanisms in sarcopenia 
Myofibers are complex structures build-up by merger of aligned myocytes (myotubes as 
intermediates). Thus, the myofiber has a common plasma membrane confining multiple sub 
domains each supported by one myonucleus. According to morphometric analysis the ratio 
myofiber volume to a myonucleus remains fairly constant suggesting an optimal size of the 
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domain supported by the machinery of one myonucleus. The impressive increase in muscle 
mass during late fetal and postnatal development but also in conditions of repair in adult 
muscle across life-span is dependent on recruitment of myogenic progenitors from the 
resident satellite cells (SC) in the stem cell niche (Kadi et al., 2005). SCs remain quiescent 
until activation through trophic stimuli e.g. IGF-1 and Notch-related signaling (Carlson et 
al., 2008). The activity of the SC pool is under the influence of several signaling pathways, 
enhancing or inhibiting SC proliferation, such as Wnt-Catenin, DeltaL/Jagged1-Notch or 
Smad2/3- TGF-/Activin/Myostatin (Carlson et al., 2008; Zammit, 2008).  
 
 
Fig. 1. Changes in fiber size and occurrence of nuclei with a central location in aged rat 
soleus muscle. Eosin-Htx staining of soleus cross sections (8m) showing (A) young adult 
muscle where central nuclei (arrow) and very small fibers (double arrow) are infrequent. In 
early aging (B) fiber size becomes more irregular and the frequency of very small fibers 
increases (arrows). At advanced age (C) fiber size is highly irregular and centrally located 
nuclei are frequently occurring. Original micrographs shot with a x20 dry objective. 
A B 
C 
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The signaling events leading to myofiber atrophy converge onto members of the FOXO 
family of transcription factors, which in an active state induce atrophy by increased 
proteasome degradation of myofibrillar proteins (Bodine et al., 2001; Sacheck et al., 2007; 
Sacheck et al., 2004; Sandri et al., 2004; Stitt et al., 2004). Recently, it was discovered that the 
signaling pathway that activates FOXO also induces an increased degradation through 
autophagy and lysosomal degradation (Sandri et al., 2006; Solomon and Bouloux, 2006). 
This “atrophy program” is activated in a range of conditions such as disuse, denervation 
and systemic diseases (Solomon and Bouloux, 2006). Conversely, myofiber contraction and 
growth signals (e.g. IGF-1) acting via protein kinase B, mTOR, and pgc-1 induce synthesis 
of myofibrillar proteins, deactivation of FOXO and, in parallel, adaptation of the energy 
producing machinery (idem). The Activin A/myostatin pathway, acting on Act receptor IIB 
upstream of Smad, can activate myofibrillar proteolysis (i.e. induce muscle fiber atrophy) 
and depress SC proliferation (Zhou et al., 2010). This creates a regulatory link between 
cellular anabolism & catabolism and SC activation & deactivation which should work in 
concert in conditions with atrophy and hypertrophy, respectively.  
A growing body of evidence suggests that loss of muscle mass in elderly occurs through 
mechanisms more complex than those involved in disuse and disease atrophy in younger 
individuals (Altun et al., 2010; Edstrom et al., 2007; Edstrom and Ulfhake, 2005). In humans 
and rodents alike, a number of mechanisms have been suggested to underpin sarcopenia: 1) 
loss of innervation 2) disuse 3) impaired maintenance and repair including decline in endo-, 
para- and autocrine signaling (e.g. IGF-1) 4) systemic inflammation 5) imbalance between 
protein synthesis and degradation and 6) poor nutrition (Adamo and Farrar, 2006; Attaix et 
al., 2005; Paddon-Jones and Rasmussen, 2009; Roth et al., 2006; Solomon and Bouloux, 2006). 
However, awaiting more definitive evidence it remains unclear if the mechanism behind 
loss of muscle mass in elderly is different from that operating in muscle atrophy in young 
individuals. It should be noted that the progress over the past decade in our understanding 
changes in muscle mass in health and disease stems mainly from work done in laboratory 
animals, in particular rodents, and highlights: 
1. Impaired regeneration of myonuclei from SCs. The satellite cell pool has been reported 
to be reduced in aged individuals and the frequency of myonuclear apoptosis to 
increase, however, these changes have not been directly associated with the loss of 
muscle mass in sarcopenia. A reduced SC pool could be consequence of an imbalance of 
SC recruitment/activation and the replenishment of the SC pool (see above). 
Furthermore, reports suggest also that age-induced changes in the microenvironment 
influence utilization of the SC through negative effects on proliferation and 
differentiation of the SCs and that in the aged the SCs are not activated on demand as in 
adults (Carlson et al., 2009). Importantly, inhibition of, or failure, to activate SC may 
augment proliferation of other progenitor cells known to co-exist in the skeletal muscle 
(Christov et al., 2007). An interplay exists between myogenic cells and fibro/adipogenic 
cells, and myogenic cells are known to inhibit fibro/adipogenic cells in the SC niche 
(Rodeheffer, 2010). In animal models this has demonstrated to influence muscle 
regeneration i.e. the scar tissue formation and fat storage in the skeletal muscle (Fuso et 
al., 2010), i.e. well-established features of the sarcopenic muscle.  
2. Loss of innervation. Observations in aged human skeletal muscle have shown loss of 
myofibers, myofiber-atrophy, a selective vulnerability of type IIa fibers and fiber-type 
grouping suggesting that an underlying mechanism is a progressive age-dependent 
denervation (Larsson, 1995). Direct observations in animal models have shown both a 
progressive denervation (Valdez et al., 2010a) and a dramatic increase in fibers re-
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expressing the embryonic isoform of myosin (eMyHC; Fig. 2) (Edstrom and Ulfhake, 
2005) while the expression levels of adult MyHC isoforms decline (Altun et al., 2007b). 
In related work using a denervation/re-innervation animal model we have obtained 
evidence that the re-expression of nicotinic acetylcholine receptor subunit gamma 
(nAChR-) is a reliable marker for muscle denervation (Grönholdt-Klein et al., in 
preparation) and in animal models on sarcopenia we consistently find a dramatic 
increase in nAChR- expression. Earlier work also showed that spinal motoneurons 
innervating aged atrophic skeletal muscles show a regenerative phenotype suggesting 
an impaired contact with the target myofibers (Johnson et al., 1995). Combined, these 
observations suggest denervation as a significant component of sarcopenia. 
3. Protein degradation and proteotoxicity. Accumulation of damaged proteins is a hallmark 
of aging that is believed to reflect increased imbalance between generation and 
scavenging of radicals, and/or decreased ability to degrade damaged proteins (Harriman 
et al., 1970). A number of studies have reported on an accumulation of oxidatively 
damaged proteins in aged rodent muscle (Cai et al., 2004; Clavel et al., 2006) as well as 
increased levels of chaperones that selectively bind unfolded proteins (Clavel et al., 
2006; Ferrington et al., 2005). Several groups have published observations suggesting a 
decreased proteasomal proteolysis as a mechanism for the buildup of worn-out and 
otherwise damaged proteins in aged rodent skeletal muscle (Ferrington et al., 2005), 
however, it is hard to reconcile such a reduced rate of proteolysis with the general loss of 
skeletal muscle mass characteristic of aging (sarcopenia).  
 
Fig. 2. Re-expression of the embryonic myosin (eMyHC) in the soleus muscle of an aged 
mouse. Immunofluorescence micrograph of an 8 m thick cross-section through the mid 
portion of a soleus muscle from a 28 month-old C57BL/6J mouse. Light profiles often with 
an irregular out-line and small size indicate fibers expressing embryonic MyHC probably 
caused by an age-related loss of innervation. Original magnification x20. 
www.intechopen.com
 Cellular Degradation Machineries in Age-Related Loss of Muscle Mass (Sarcopenia) 273 
This chapter will focus on the main cellular degradation machineries and our current 
understanding of how age-related changes in these systems impact skeletal muscle integrity. 
2. Regulated proteolysis  
Regulated proteolysis is instrumental for such diverse cellular processes as signaling, cell 
cycle progression, and apoptosis. Protein and organelle degradation enables recycling of the 
building blocks and is also an important survival response to starvation, whereby proteins 
are degraded to supply the organism with fuel for energy production. The accumulation of 
aggregates of misfolded proteins is a hallmark of cells and tissues of aged organisms, and 
protein aggregation occurs when damaged or partially unfolded proteins are not efficiently 
degraded. Disposal of proteins is in most conditions a selective and coordinated process, 
handled mainly by two cellular proteolytic systems, the ubiquitin-proteasomal system (UPS) 
and autophagy-lysosomal system (ALS). 
2.1 The ubiquitin proteasomal system (UPS) 
Work over the last 25 years has established the importance of regulating protein 
ubiquitination in a wide range of cellular functions including cell cycle control, 
transcriptional regulation, and diverse aspects of cell signaling. Lysine48 polyubiquitination 
targets proteins for degradation by the proteasome, a highly selective mechanism by which 
multiple cellular processes are being modulated. Collectively, the proteasome and enzymes 
involved in ubiquitination are referred to as the ubiquitin proteasomal system (UPS) (Fig. 3).  
 
Fig. 3. The ubiquitin proteasomal system.  Cartoon of the different components of the 
ubiquitin-proteasomal system described in the text. 
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However, ubiquitination does not only associate with proteasomal degradation, other forms 
of ubiquitination play roles in such diverse processes as transcriptional regulation, 
endocytosis, DNA modifications and stabilization of protein complexes (Harper and 
Schulman, 2006). Ubiquitin (Ub) is transcribed as precursor proteins from 4 genes and after 
cleavage to monomeric Ub, Ub-conjugation occurs through an enzymatic cascade where the 
E3-ligases (>600 E3 ligases have been identified so far) provide for target specificity. Prior to 
cleavage in the proteasome of a lys48 poly-Ub conjugated protein, the Ub-recognition signal 
is removed (Fig. 3). This serves to enhance passage of the targeted protein into the catalytic 
chamber and will also free ubiquitin for reuse and hinder the proteasomes to be 
preoccupied with destroying Ub [itself] (Hanna et al., 2007; Koulich et al., 2008). Hydrolysis 
of bound Ub and processing of Ub precursor proteins is accomplished by members of the 
large group of deubiquitinating enzymes (DUBs) (>90 members identified so far); DUBs are 
cysteine proteases that can be divided into distinct subfamilies based on sequence 
similarities and likely mechanism of action (reviewed in Nijman et al., 2005). Since DUBs 
can reshuffle ubiquitin from poly- to mono- or multi-ubiquitin chains, they are not only 
important for protein half-life but probably all cellular processes that involve ubiquitination 
of proteins (Clague and Urbe, 2006). 
2.2 Activation of the UPS in sarcopenia 
Because available data on the integrity of the UPS in the elderly was controversial we 
examined in 30-month old Sprague-Dawley rats the effects of aging on the content and 
activity of 26S proteasomes, proteasome-associated regulatory proteins and various other 
components of the UPS, including multiple DUBs (Altun et al., 2010). Muscles of these aged 
animals undergo marked atrophy compared to muscles of young adult animals and this 
age-related atrophy could be impeded if the animals were maintained on a restricted diet 
(Altun et al., 2007a). Analysis of proteasome protein content and proteasome degradation 
capacity in these animals revealed a 2-3 fold increase in proteasomes in the aged muscle. 
The increase in 26S proteasomes was suppressed completely in aged animals maintained on 
a restricted diet (30% of the consumption recorded for rats having free access to food). Since 
muscle wasting was reduced in these animals, these findings suggest that the buildup of 
proteasomes contributes to the loss of muscle mass in aged animals. In support of this 
notion we found that the levels of proteasome subunits in aged skeletal muscle were 
inversely correlated with muscle weight (subunits 1: r=-0.71, p<0.05; 5: r=-0.69; p<0.05), 
and no such inverse relationship was found in muscles of adult rats or aged animals 
maintained on dietary restriction (Altun et al., 2010). However, the underlying mechanism 
of this accumulation remains unclear. In contrast to muscles atrophying due to disuse, 
fasting or various systemic diseases, the age-related accumulation of proteasomes occurred 
without any increase in corresponding mRNAs. Thus, the accumulation of proteasomes in 
aged muscle must be due to enhanced subunit translation, more efficient assembly of the 
26S particles, or slower degradation of the 26S particles (see below under 2.4). 
Previous reports suggested that age-related decrease in the proteasome’s peptidase activities 
were due to oxidative modifications (Bulteau et al., 2000; Conconi et al., 1996; Ferrington et 
al., 2005; Grune et al., 2001; Hayashi and Goto, 1998; Keller et al., 2000). However, we could 
not observe such defect in degrading capacity towards a range of substrates including 
ubiquitinated native proteins (Fig. 4). Instead, our data indicates that proteasome content 
increases during sarcopenia, and that these particles retain their full ability to function in 
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protein breakdown. Together these findings suggest that the enhanced capacity of the UPS 
may be a response to the increased generation of damaged polypeptides. Strong support for 
this conclusion is our finding of elevated levels of the ubiquitin ligases, CHIP and E6AP, in 
muscle of aged animals. CHIP ubiquitinates misfolded or mutated proteins bound to Hsp70 
or Hsp90 (Connell et al., 2001), and recently a similar function in cellular quality control has 
been reported for E6AP (Mishra et al., 2009). Moreover, most of these conclusions about a 
negative impact of aging on proteasomal degradation in muscle were based exclusively on 
measurements of the 20S core particle. Although some degradation of unfolded or 
denatured proteins may occur by the free 20S (Jariel-Encontre et al., 2008), the bulk of 
proteasome-mediated degradation, even of oxidatively damaged proteins (Medicherla and 
Goldberg, 2008), seems to require the 26S proteasome and ubiquitylation of the substrate. 
 
Fig. 4. Degradation capacity towards different substrates of proteasomes isolated from 
triceps surae muscle of adult rats (Ad-AL), aged (Ag-AL) and aged rats maintained on 
dietary restriction (Ag-DR) (original data reproduced from Altun et al., 2010). The higher 
content per unit muscle mass of proteasomes in aged (Ag-AL) muscles is paralleled by a 
corresponding increase in degradation of synthetic peptides designed for the chymotryptic 
and caspase sites of the proteasome (A) as well as casein (B). In (C) degradation of a native 
ubiquitinylated protein is shown illustrating that we could not detect any impairment of the 
degradation capacity of 26S proteasomes isolated from aged rats muscle. Further details on 
experimental design in Altun at al., 2010. 
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A decline in the cell’s pool of free ubiquitin can limit the rate of proteolysis by the proteasome 
(Hanna et al., 2003; Kimura et al., 2009) and free ubiquitin is in turn released during 
degradation of ubiquitylated proteins by the DUBs associated with the 26S proteasome. Thus, 
in order to achieve high degradation rates, the capacity for deubiquitylation probably needs to 
be increased too. Using mechanism-based probes to assess the state of DUB activity and 
expression (Altun et al., 2010), eleven DUB-enzymes were found to be strongly up-regulated in 
the muscles of aged rats; including USP14 and Uch37 which are known to be associated with 
the 26S proteasome. USP14 and UCH37 trim off ubiquitin from the polyubiquitin chain and 
release ubiquitin monomers for re-use. In addition, USP14 controls gate opening into the 20S 
proteasome and facilitates substrate degradation (Peth et al., 2009). On the other hand, the 
yeast homolog of USP14, Ubp6, regulates the overall rate of proteolysis and appears critical in 
replenishing the free ubiquitin pool in yeast (Hanna et al., 2003; Hanna et al., 2007). Similarly, 
USP5 hydrolyses anchorless ubiquitin chains (Reyes-Turcu et al., 2006; Reyes-Turcu et al., 
2008) and appears to work downstream of Rpn11, an intrinsic DUB on the proteasome, to 
prevent the binding of free ubiquitin chains to the 19S, which would inhibit proteolysis. 
Together these data illustrate important roles for deubiquitylation in the aged muscle, 
probably ensuring a supply of ubiquitin for enhanced proteolysis but perhaps also serving 
additional regulatory functions. 
Loss of muscle mass can occur through increased protein degradation but also decreased 
protein synthesis or through some combination of these responses. With aging, sarcopenia 
develops over months to years depending on the species, unlike the rapid loss of muscle 
weight induced by fasting, disuse, and in various catabolic diseases, where marked atrophy 
(20-50% loss) can occur in rodents in several days. In these latter types of rapid atrophy, as 
described above, there is a common program of changes in the transcription of a set of 
atrophy-related genes (Lecker et al., 2006; Lecker et al., 2004; Sacheck et al., 2007). Several of 
the biochemical changes observed in aged atrophic muscle clearly distinguish them from 
those undergoing rapid atrophy in adult animals. Upon denervation or fasting, the atrophy-
specific ubiquitin ligases, Atrogin-1/MAFbx and MuRF1, are induced by members of the 
FOXO family of transcription factors, and this induction is essential for the rapid weight loss 
(Bodine et al., 2001; Lecker et al., 2006; Sandri et al., 2004). Inhibition of FOXOs prevents 
their induction and the loss of muscle mass upon denervation, fasting, or glucocorticoid 
treatment (Sandri et al., 2004). In contrast, in the aged muscles, mRNAs for Atrogin-
1/MAFbx, MuRF1 and the Ub-conjugating enzyme, E2-14K, were unchanged or lower than 
adult levels (Edstrom et al., 2006). Also, treatment with the glucocorticoid dexamethasone 
failed to induce Atrogin-1/MAFbx or MuRF1 or to cause muscle wasting, as it does in adult 
animals (Bodine et al., 2001; Gomes et al., 2001). However, MuRF1 protein increased in aged 
muscle, while Atrogin-1/MAFbx protein decreased (in accord with the mRNA data). 
Another distinction between sarcopenia and rapid atrophy is that the ubiquitin ligases, 
CHIP and E6AP, increased markedly in the aged muscle, though they do not rise in rapidly 
atrophying muscles. Their induction may reflect adaptations in the aged muscle to eliminate 
more efficiently misfolded proteins.  
In summary, the finding of increased content of proteasomes and other UPS components 
(e.g. MuRF1) argues that proteolysis also increases in these muscles and may contribute to 
muscle wasting in the aged rats. Dietary restriction decreased levels of proteasomes and 
several other UPS components toward the levels in adult animal and partially inhibited the 
development of sarcopenia. 
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2.3 Accumulation of ubiquitinated proteins in sarcopenic muscles 
During muscle atrophy in adult animals induced by fasting, disuse or disease, there is a 
marked increase in protein ubiquitination and proteolysis, especially of myofibrillar 
components (Lecker et al., 1999; Mitch and Goldberg, 1996). If the rate of ubiquitination 
exceeds the rate of Ub-dependent proteolysis, Ub-protein will accumulate; this will also 
occur if proteins are damaged or rearranged (multimeric aggregates) in a way that hinders 
normal proteasomal degradation. Immunoblotting of muscle extracts with an anti-ubiquitin 
antibody reveal that the muscles from aged rats contained greater amounts of ubiquitylated 
proteins than those from adult rats (Fig.5B; see also (Altun et al., 2010)). An increase in free 
ubiquitin and ubiquitin conjugates with aging was also reported by others in rat muscles 
(Cai et al., 2004; Clavel et al., 2006). Since the 26S proteasomes isolated from aged muscle are 
fully active in degrading ubiquitylated proteins, the elevated levels of ubiquitylated proteins 
strongly suggest higher overall rates of protein ubiquitylation that exceed the rates of 
conjugate degradation or the formation of nondegradable Ub-protein aggregates. 
Immunohistochemical analysis (using the same antibody towards ubiquitin) show that some 
of the fibers in aged skeletal muscles contain Ub+ deposits (Fig. 5A). 
 
Fig. 5. Amount of ubiquitylated protein is increased in aged skeletal muscle. (A) shows 
micrograph of an aged soleus muscle cut along fiber length and processed with an antibody 
that recognizes ubiquitylated proteins using the ABC peroxidase technique. Ub+ protein 
deposits appear in black (arrows) and vary in size but are usually localized to the peripheral 
domain of the fiber (original micrograph was taken with an x20 dry objective). (B) shows a 
immunoblot of muscle extract from adult, aged and aged rats maintained on dietary 
restriction (DR)  using the same antibody as in (A). The amount of Ub-proteins is clearly 
higher in aged fed ad libitum, while aged rats on DR are more similar to adults. 
2.4 The autophagy lysosomal system (ALS) 
Ubiquitination is also involved in processes leading to abrogation of signal transduction and 
targeting of the receptors for destruction by the autophagosome lysosomal system (ALS; Fig. 
6). One example is the monoubiquitin-dependent endocytosis and degradation of epidermal 
growth factor receptor (Haglund et al., 2003; Mizuno et al., 2005). Degradation through the LS 
involves not only proteins but also damaged cell organelles and large complexes (Cuervo et 
al., 2005; Terman and Brunk, 2006; Terman et al., 2006). Multiple vesicles that constantly fuse 
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and fission constitute the lysosomal system. Lysosomal degradation is initiated through 
several pathways based on the substrate delivering mechanism (Fig. 6): Endocytosis (clathrin 
mediated pinching-off of membrane patches with/without inclusion of extracellular material) 
occurs and the resulting particle is referred to as an endosomes (carrying rab5). Endosomes 
can then develop into late endosomes, which are equipped with enzymes delivered by 
secretory vesicles from the trans-Golgi-network and sorted by mannose-6-phosphate 
receptors, which are markers for late endosomes. Late endosomes may also fuse with 
lysosomes (then they lose the mannose-6-phosphate receptors).   
A second route is chaperone mediated autophagy (CMA), which targets proteins carrying a 
pentapeptide (KFERQ) motif that is recognized by the chaperon Hsc73 and through binding to 
the LAMP-2A receptor (lysosome associated membrane protein 2A; a marker of the lysosome), 
the targeted protein is taken up and degraded in the lysosomal lumen (Fig. 6). The major route 
for organelles and proteins targeted for lysosomal degradation is via autophagy, a process 
controlled by the autophagy-conjugase complexes Atg12-Atg5 and Atg8-Atg3 (Atg, 
autophagy related genes) whereby in-bulk cytoplasm becomes entrapped in a double 
membrane forming an autophagosome (autophagic vacuole, AV) (Terman and Brunk, 2004).  
 
 
 
Fig. 6. Schematic drawing of the autophagy-lysosomal system. The different cargo routes 
to lysosomal degradation are illustrated and described in the text. 
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Subsequently, the autophagosome fuses with a lysosome for degradation under the formation 
of an autophagolysosome (Fig. 6). With the formation of the AV, the Atg conjugase complexes 
disassociate, but the Atg 8 (the mammalian homologue is MAP-LC3) remains in the ALS until 
degradation. While, Atg8 may be a marker for AVs and [by its elimination also] the 
completion of this degradation route, the autophagy conjugase complexes indicate ongoing 
ALS formation/autophagy. The role of the autophagy-lysosomal system was not widely 
recognized until it was demonstrated that cathepsins (D and B+L, respectively; (Felbor et al., 
2002)) and autophagy (Hara et al., 2006) were non-redundant for a normal development and 
that cells rely on a basal level of autophagy to keep them free of worn-out organelles and 
aberrant proteins. 
2.5 Signs of distress of the ALS during aging 
There is solid evidence for the engagement of autophagy in major human degenerative 
diseases and in normal aging. A decreased capacity of the lysosomes to degrade waste will 
cause a build-up of damaged organelles and proteins disturbing cell homeostasis; and e.g. 
accumulation of dysfunctional mitochondria in aging cardiomyocytes, myofibers and neurons 
has been reported. Recently, several studies have shown that the induction of autophagy, by 
intervention of the above discussed signaling pathways, increase cellular clearance of aberrant 
proteins also when the normal degradation route operates via the proteasome or through 
CMA. The load on the ALS in normal aging is evident from the dramatic accumulation of 
lipofuscin by time (Fig. 7 G-H) and the concomitant upregulation of markers of lysosomal 
proteolysis. Lipofuscin forms due to iron-catalyzed intralysosomal peroxidation and its 
accumulation in the lysosomal compartment seems to set down the capacity of autophagy 
(Brunk and Terman, 2002). Oxidative stress, even mild stress, accelerates the formation/build-
up of lipofuscin (Kurz et al., 2008) and stress can cause lysosomes to become leaky due to 
intralysosomal reactive iron mediated Fenton- reactions with production of hydroxyl radicals 
and resulting labilization of the lysosomal membrane. Even though the pH is suboptimal, 
several of the lysosomal enzymes are apparently proteolytically active if released to the cytosol 
and may then trigger cell degeneration/death (Chu, 2006). 
Analysis of atrophic skeletal muscle in aged rats (Altun et al., 2007b) revealed increased levels of 
molecules involved in iron transport (transferrin), binding (ferritin), as well as  iron response 
element binding protein-1 activity; combined these observations suggest increased load on the 
iron-handling machinery. Measurements of iron levels revealed a significant accumulation in 
the aged skeletal muscle, providing further support for iron loading in senescence. Iron-loading 
increases the risk for common hallmarks of aging such as DNA damage, protein oxidation and 
misfolding, and lipid peroxidation and may accelerate the accumulation of lipofuscin (see 
above). Iron-load is not exclusive to aging-related muscle wasting, but is also evident in 
experimental disuse atrophy (Kondo et al., 1992) and iron-restriction has been shown to be 
beneficiary in certain inherited myopathies (Bornman et al., 1998).  
3. Cross talk between the UPS and the ALS 
Until recently the UPS and the ALS were considered as independent pathways for protein 
degradation. The UPS offers a fast and highly specific mechanism to remove selected 
proteins. However, the targeted protein must be a monomer and unfolded to be able to 
enter the proteolytic lumen of the proteasome. The ALS represents a partly overlapping, 
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partly complementary degradation route, taking care of folded and aggregated proteins as 
well as large complexes and organelles with heterogenic building blocks (carbohydrates, 
lipids and proteins). However, several lines of evidence indicate intersections between these 
two pathways. In neurons treated with proteasome inhibitors, aggregate-prone proteins 
normally degraded by the UPS are degraded by autophagy (Cuervo et al., 2004). Two recent 
papers also provide evidence that induction of the UPS and LS may occur via a common 
pathway in skeletal muscle (Mammucari et al., 2007; Zhou et al., 2010).  
Several studies report that with increasing age the capacity for lysosomal proteolysis is 
reduced in postmitotic cells including myofibers, while the capacity to degrade proteins 
through the UPS is enhanced (see above). Given that transcription of proteasome subunits and 
the expression of proteins involved in the assembly of the 20S were unaltered in in aged 
rodents, we hypothesized that proteasome particles accumulate in muscles during aging 
because they are not degraded at the same rate as in young adults. It is currently unknown 
which mechanism is responsible for the degradation of proteasomes, although the lysosomal 
pathway was suggested to accomplish this task in hepatocytes (Cuervo et al., 1995). To test 
whether this mechanism may be present in skeletal muscle cells, we treated adult rats (Fig.7A-
C) and rat muscle derived cell line L6, respectively, with the lysosomal inhibitor chloroquine 
followed by quantitation of proteasome levels and activity (Fig.7A-F). In these experiments, 
we observed an accumulation of proteasomes accompanied by increased active site labeling in 
the muscle extracts from both chloroquine treated animals and L6 cell extracts. 
 
Fig. 7. Compromised lysosomal proteolysis increases proteasome content and activity.  
(A-C) Adult animals treated with chloroquine (50mg/kg) for 16 days (1 injection/day).  
(A) Immunoblot against proteasome subunit b5 to assay proteasome content (top) and 
proteasome labeling (bottom) using the active site directed probe DansylAhx3L3VS.  
(B) Individual bands were quantified for b5 content and (C) active site directed probe 
DansylAhx3L3VS labeling of the b1, b2 and b5 catalytic subunits. (D-F) Rat muscle derived 
cell line L6 was treated when confluence reached about 70% with 50mM NH4Cl or 100mM 
chloroquine for 24 hour before lysis. Immunoblot against proteasome subunit b5 to assay 
proteasome content (D top panel, E) and active site labeling of the b1, b2 and b5 catalytic 
subunits (D lower panel, F). b-actin was used as loading control for immunoblotting (data 
not shown). All error bars are standard deviations. Statistical significance: * p<0.05, ** p<0.01 
and *** p<0.001. (G, H) Lipofuscin accumulation in aged skeletal muscle. Unstained 
longitudinal sections of soleus muscle form adult (A) and aged (B) rats show increased 
content of lipofuscin autofluorescence in aged sarcopenic muscle. The bar represents 100m 
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As in the aged rat muscles, the accumulation of proteasomes following lysosomal inhibition 
was not induced by a transcriptional up-regulation (data not shown) and therefore results 
likely from a reduced clearance of proteasomes due to an impairment of lysosomal function. 
Consistent with this, we observed lipofuscin accumulation in the aged rat muscle tissue 
(Fig.7 G and H). In addition, Cuervo and colleagues reported that autophagy declines in 
liver with aging but this effect is reduced by dietary restriction (Hanna et al., 2003; Watts et 
al., 2004). Activation of autophagy in muscle by dietary restriction could explain our 
findings that this regime prevented the increase in proteasomes with age without any 
change in proteasome mRNA levels. Combined these observations suggest the ALS as a 
candidate pathway for proteasomal degradation awaiting more definitive evidence. 
4. Concluding remarks 
Human cross-sectional and longitudinal studies have consistently demonstrated a gain in fat 
mass and decline in lean mass during aging. Although aging-related muscle wasting, or 
sarcopenia, is widely recognized it still remains poorly understood. The reduced functional 
muscle mass is associated with increased morbidity and reduced quality of life. To maintain 
integrity muscle myofibers rely on degradation pathways to keep clean from worn-out 
organelles and damaged proteins. Our current understanding is that the autophagy-
lysosomal system is in distress possibly driven by an age-dependent accumulation of 
reactive iron, while contrary to the widespread view, the complementary pathway for 
degradation of proteins, the UPS, is enhanced. The age-dependent increase in the muscle 
specific ubiquitin-ligase MuRF and ubiquitin-dependent proteasomal proteolysis is 
expected to occur in the progression of sarcopenia since this route is nonredundant for 
degradation of myofibrillar proteins. In addition, the UPS in aged skeletal muscle shows 
adaptations to an increased demand on degradation of aberrant proteins and an 
accumulation of ubiquitinated proteins. Combined these stigmata suggest that aged 
myofibers may be at risk to enter a state of proteotoxicity.  
Normal skeletal muscles have a good capacity to regenerate following wasting conditions 
such as disuse. The muscle regenerative response relies on signaling that evokes satellite cell 
replication and asymmetric division generating offsprings that will differentiate to myocytes 
via the myoblast stage. Such cells are then incorporated into the myofiber allowing it to 
grow (for example in response to an exercise stimulus). Poor capacity to regenerate muscle 
tissue at advanced age may depend on impaired signaling, exhaustion of the SC pool or 
changes in the extracellular matrix or stem-cell niche impeding the regeneration and 
incorporation of myoblasts into existing/regenerating myofibers (for references see 
Introduction). Assessments of  the regenerative drive in aged sarcopenic muscle have, 
however, shown that myogenic differentiation factors are upregulated and that there are 
overt signs of incorporation of new nuclei into existing fibers (Fig. 1B,C; (Edstrom and 
Ulfhake, 2005)). Still, regeneration fails and tissue atrophy progresses.  
The triggering mechanism for the age-dependent fiber atrophy and fiber loss remains 
enigmatic. However, several lines of evidence converge towards support of the 
“neurogenic” theory (Gutman and Hanzlikova, 1972), which stipulates that sarcopenia is 
driven by a successive drop-out of motoneurons. Early evidence in favor of this theory was 
the observation of fiber-type grouping and also histological examination revealing 
regressive changes at the neuro-muscular junctions. The strongest argument against this 
theory is the absence of unbiased evidence of a significant age-dependent loss of 
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motoneurons. However, as discussed at length elsewhere (Johnson et al., 1995) the 
denervation may be a peripheral process primarily involving subdomains of the motor 
axon’s terminal arborization within a motor unit (see also (Valdez et al., 2010b)). Failure to 
maintain the distant axon arbor could cause branches and terminals to degenerate leaving 
myofibers vacated from innervation. As this process progresses more and more fibers will 
be denervated and read-outs validating this process are the increase in expression of the 
nAChR- subunit (Gronholdt-Klein et al., in preparation) and embryonic myosin (Edstrom 
and Ulfhake, 2005); and it should be noted that these proteins are re-expressed by young 
adult myofibers upon denervation. As denervation becomes significant, it will trigger the 
atrophy program by which MuRF1 and other enzymes will accelerate proteasomal 
myofibrillar protein degradation (see above). Recently, further direct histological evidence 
for this process was obtained by Valdez and coworkers (Valdez et al., 2010b). These authors 
also showed that exercise and dietary restriction slow-down the progression of age-
dependent denervation, at least the latter observation is consistent with our biochemical 
data on the UPS (see above). It will be important to seek proof of principle for the 
neurogenic theory in experimental animal models followed by validation in humans since it 
will impact the development of strategies to impede sarcopenia in humans. 
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